Quotient Clinical Expands US Operations
PTSM: Pharmaceutical Technology Sourcing and Management
Quotient Clinical’s addition of CDMO QS Pharma increases the company’s footprint in the US an adds high potency molecule capability.
Quotient Clinical announced on Feb. 14, 2017 the acquisition of QS Pharma, a contract development and manufacturing organization based near Philadelphia, from Charles River Laboratories International, Inc. The acquisition increases Quotient’s presence in the US and, will enable the company to replicate its Translational Pharmaceutics platform in America, according to a press statement. On Feb. 6, 2017, Quotient announced the acquisition of SeaView Research, a Florida-based clinical pharmacology business.
Founded in 2002, QS Pharma specializes in the formulation development and manufacturing of small-molecule drug products and supports customer programs through all stages of development and commercialization, including work with high potency molecules.
Quotient’s Translational Pharmaceutics platform integrates clinical testing with formulation development and real-time GMP manufacturing; more than 100 pharmaceutical and biotech companies have chosen Translational Pharmaceutics to accelerate the development of their products, the company reports.
Source: Quotient Clinical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
